I'm a growth investor, and frankly it is very hard to find growth in the US market - all my spare time is spent trying to find ideas outside of commodities and/or non commodities that I already own - and the pickings are slim. Even technology which many people see as a growth sector is chock full of older established slower growth companies, and aside from a handful I just don't see much growth there. Financials? Very few. Retail? hah. I go sector by sector and see very little growth out there - even in the healthcare field. So it is hard to diversify across sectors when you are looking for growth - because most of the growth is very concentrated. One group I have liked in healthcare are the medical contract research organizations - i.e. drug research outsourcing. No FDA approval risk, no government reimbursement risk, etc. I have one stock in this sector, a Chinese company called WuXi PharmaTech (WX) - which after purchasing last fall (Nov 5: Two New Foreign Positions Added Today) has been a total dog despite some very good earnings reports (Mar 12: WuXi PharmaTech - Very Good Earnings). I don't have a large position thankfully since the stock has recently fallen off a cliff but it is a perplexing situation. Most of the US companies have very high valuations so I have been reluctant to add any, and an Irish company I've been in, in the past ICON (ICLR) is also pricey. (Feb 21: ICON with a Solid Report)

However, one of the US players, Parexel International (PRXL), has fallen precipitously the past few days and its now on my radar - I like relative value so when a stock falters it begins to interest me. However, a few caveats - it is the only US company to be falling like this so that's a red flag, and it's temporarily fallen so hard it is now below its 200 day moving average. So it could portend something company specific is happening; with earnings on the 23rd I have been debating whether to add this name. Still debating.... one could buy here, and if there is an earnings blowup, be down 30% instantly on the 24th of April. I always get suspicious of this type of price behavior because if nothing else, Wall Street is a game of insiders - and this sort of action might be people "in the know" getting out first... so I am going to hold off, and if the earnings report is solid and the stock remains in this level, I will probably buy then as the stock has fallen from the mid $27s to the mid $23s (15%) in just a week, which in this sort of sector is a huge move.